Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer: Results From BOLERO-2 (vol 34, pg 419, 2016)

被引：1
|
作者：
Hortobagyi, Gabriel N.
Chen, David
Piccart, Martine
Rugo, Hope S.
Burris, Howard A.
Pritchard, Kathleen I.
Campone, Mario
Noguchi, Shinzaburo
Perez, Alejandra T.
Deleu, Ines
Shtivelband, Mikhail
Masuda, Norikazu
Dakhil, Shaker
Anderson, Ian
Robinson, Douglas M.
He, Wei
Garg, Abhishek
McDonald, E. Robert, III
Bitter, Hans
Huang, Alan
Taran, Tetiana
Bachelot, Thomas
Lebrun, Fabienne
Lebwohl, David
Jose, Baselga
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.18.02265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：355 / 355
页数：1
相关论文
共 50 条
  • [41] Budget impact analysis of everolimus for estrogen receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients in the United States
    Xie, J.
    Diener, M.
    De, G.
    Yang, H.
    Wu, E. Q.
    Namjoshi, M.
    CANCER RESEARCH, 2012, 72
  • [42] Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer
    Cheung, Yee-Ming M.
    Cromwell, Grace E.
    Tolaney, Sara M.
    Min, Le
    McDonnell, Marie E.
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 192 (02) : 303 - 311
  • [43] Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer
    Yee-Ming M. Cheung
    Grace E. Cromwell
    Sara M. Tolaney
    Le Min
    Marie E. McDonnell
    Breast Cancer Research and Treatment, 2022, 192 : 303 - 311
  • [44] Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
    Patrick Neven
    Hope S. Rugo
    Sara M. Tolaney
    Hiroji Iwata
    Masakazu Toi
    Matthew P. Goetz
    Peter A. Kaufman
    Yi Lu
    Nadine Haddad
    Karla C. Hurt
    George W. Sledge
    Breast Cancer Research, 23
  • [45] Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
    Neven, Patrick
    Rugo, Hope S.
    Tolaney, Sara M.
    Iwata, Hiroji
    Toi, Masakazu
    Goetz, Matthew P.
    Kaufman, Peter A.
    Lu, Yi
    Haddad, Nadine
    Hurt, Karla C.
    Sledge, George W., Jr.
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [46] A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer
    Zoe Kemp
    Alison Jones
    Advances in Therapy, 2011, 28 : 603 - 614
  • [47] ADVERSE EVENT MANAGEMENT DURING TREATMENT WITH ALPELISIB FOR HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER
    Colella, Sarah
    Lacouture, Mario
    Farooki, Azeez
    Juric, Dejan
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [48] A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer
    Kemp, Zoe
    Jones, Alison
    ADVANCES IN THERAPY, 2011, 28 (08) : 603 - 614
  • [49] Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer
    Andre, Fabrice
    Neven, Patrick
    Marinsek, Nina
    Zhang, Jie
    Baladi, Jean-Francois
    Degun, Ravi
    Benelli, Giancarlo
    Saletan, Stephen
    Jerusalem, Guy
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (06) : 1007 - 1016
  • [50] Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre
    Twelves, Chris
    Cheeseman, Sue
    Sopwith, Will
    Thompson, Matthew
    Riaz, Majid
    Ahat-Donker, Necibe
    Myland, Melissa
    Lee, Adam
    Przybysz, Raymond
    Turner, Stuart
    Hall, Geoff
    Perren, Tim
    BMC CANCER, 2020, 20 (01)
12345